Gilead Sciences, Inc. (GILD)
|Net Income (ttm)||301.00M|
|Trading Day||June 21|
|Day's Range||66.77 - 67.55|
|52-Week Range||55.19 - 75.59|
Gilead to Present More Than 70 Abstracts From Diverse Liver Disease Programs At The International Liver Congress™ 2021
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that more than 70 abstracts from the company's liver disease programs will be presented at The International Li...
Gilead's (GILD) wholly owned subsidiary Kite signs partnership deal with Shoreline Biosciences to develop novel cell therapies for cancer.
In the latest trading session, Gilead Sciences (GILD) closed at $67.22, marking a -0.16% move from the previous day.
Kite Pharma, a unit of Gilead Sciences Inc (NASDAQ: GILD) and Shoreline Biosciences Inc, has entered into a strategic partnership to develop novel cell therapies across various cancer targets. The colla...
Kite and Shoreline Biosciences Enter Into Strategic Partnership to Develop Novel Allogeneic Cell Therapies
SANTA MONICA, Calif. & SAN DIEGO--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), and Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogenei...
The FDA has signed off Jounce Therapeutics Inc's (NASDAQ: JNCE) Investigational New Drug (IND) application for JTX-1811, triggering a milestone payment of $25 million from Gilead Sciences Inc (NASDAQ: G...
It is hard to believe, but in just over two weeks the second quarter will come to a close and many investors will be reviewing their portfolios and making changes for the second half of 2021.
Longer-term Data for Kite's Yescarta® in Relapsed or Refractory Follicular Lymphoma Demonstrate Substantial Survival ...
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced follow-up results from the pivotal ZUMA-5 trial of Yescarta® (axicabtagene ciloleucel) – the first and only ...
Gilead Sciences (GILD) closed at $68.77 in the latest trading session, marking a -0.75% move from the prior day.
According to the High Dividend Yield Screen, a Premium feature of GuruFocus, five stocks that have a dividend yield of at least 4% and at least 10 gurus buying shares as of June are Gilead Sciences Inc....
Gilead (GILD) obtains FDA approval for the label expansion of HCV drug, Epclusa, to include children as well.
U.S. Food and Drug Administration Approves New Formulation of Epclusa®, Expanding Pediatric Indication to Treat Child...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that the U.S. Food and Drug Administration (FDA) has approved an expansion of the pediatric indication of Epclu...
Best long term hold: Abbvie or Gilead? #AskHalftime
The "Halftime Report" traders answer viewer questions in #AskHalftime.
Gilead Sciences (GILD) closed at $67.43 in the latest trading session, marking a +1.43% move from the prior day.
Gilead Sciences Inc (NASDAQ: GILD) has announced new data from the Phase 3 ASCENT study evaluating Trodelvy (sacituzumab govitecan-hziy) in relapsed or refractory metastatic triple-negative breast cance...
Kite's Tecartus® Demonstrates High Response Rate in Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leu...
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), announced today results from the primary analysis of ZUMA-3, a global, multicenter, single-arm, open-label Phase 1/2 study e...
Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have dug up Gilead Sciences, Inc. among others.
Trodelvy® Demonstrates Superior Outcomes to Standard of Care in Second-Line Treatment of Metastatic Triple-Negative B...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from the Phase 3 ASCENT study evaluating Trodelvy® (sacituzumab govitecan-hziy) in relapsed or refract...
Despite strong headwinds, there may be hope for this biotech.
Gilead Sciences' revenues are being boosted by its COVID-19 treatment, but it will still be a good investment in a post-pandemic world.
FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced that 16 abstracts representing the breadth of the Gilead-Kit...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Cowen Annual Virtual Oncology Innov...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: BofA Securities 2021 Virtual Health...
FATE reports a wider Q1 loss on increased R&D expenses.
The drugmaker is also looking for its highest sales ever in 2021 in large part because of remdesivir.
U.S. aid shipment of remdesivir arrives in India overnight
The United States sent India 125,000 vials of the anti-viral drug remdesivir Sunday night. Its the fourth assistance flight from the United States to India as a way to help combat the surge in cases.
With the trading day more than halfway over, the broader markets were sliding into the weekend.
Gilead (GILD) reports mixed results for the first quarter as the ongoing pandemic adversely impacted core HIV segment sales.
Gilead Sciences Inc (NASDAQ: GILD) reported lower than expected Q1 earnings with EPS of $2.08, slightly below the analyst consensus estimate of $2.09 but higher than $1.68 last year. Sales of $6.42 bill...
With Veklury, Gilead delivered solid revenue growth in Q1. Without the COVID drug, it was an entirely different story.
Gilead Sciences Inc. (NASDAQ: GILD) said on Thursday that its sales in the fiscal first quarter came in weaker than Wall Street estimates. Sales for its COVID-19 drug (Veklury), however, beat expectations.
Gilead (GILD) delivered earnings and revenue surprises of 0.97% and -5.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Gilead earnings, revenue both miss
CNBC's Meg Tirrell reports on Gilead's earnings. CNBC's Mike Santoli weighs in.
Gilead Sciences Inc on Thursday said its first-quarter product sales rose 16%, including $1.46 billion in sales of its COVID-19 antiviral drug remdesivir, but sales of flagship HIV and hepatitis C drugs...
Shares of Gilead Sciences (NASDAQ:GILD) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 23.81% year over year to $2.08, which missed...
FOSTER CITY, Calif.--(BUSINESS WIRE)---- $GILD #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared a cash dividend of $0.71 per share of common...
FOSTER CITY, Calif.--(BUSINESS WIRE)---- $GILD #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter 2021. “We have made strong progress in this fir...
We believe that Gilead Sciences stock (NASDAQNDAQ: GILD) is a good buying opportunity at the present time. GILD stock trades near $65 currently and it is, in fact, down 19% from its pre-Covid high of ...
Further price movement of the healthcare ETFs depend on earnings releases from some big names like Pfizer (PFE), Merck (MRK), Thermo Fisher (TMO), AbbVie (ABBV), and Gilead Sciences (GILD) that dominate...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that in response to the rapid increase in COVID-19 cases in India, the company is providing its voluntary licen...
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of l... [Read more...]
|IPO Date |
Jan 22, 1992
|Stock Exchange |
|Ticker Symbol |
In 2020, GILD's revenue was $24.69 billion, an increase of 9.98% compared to the previous year's $22.45 billion. Earnings were $123.00 million, a decrease of -97.72%.
According to 32 analysts, the average rating for GILD stock is "Buy." The 12-month stock price forecast is 74.49, which is an increase of 10.36% from the latest price.